Arcadia Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Arcadia Biosciences Inc (RKDA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Arcadia Biosciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs 82,874M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+21.6% annualized vs trailing 12 months), vs accelerating (+11.3%) for its tracked peer group.
- Growth: Arcadia Biosciences Inc generated -0.8% revenue growth year over year in Q2 2026, vs -3.8% for its tracked competitors combined.
- Profitability: Its -434.2% net margin compares with 28.0% for the peer group.
- Scale: Arcadia Biosciences Inc ranks #109 of 134 companies by market capitalization in the Oil And Gas Production industry, holding 0.0% of industry market cap.
- Peer revenue share: Arcadia Biosciences Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.59M compares with $0.65M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RKDA Sales vs. its Competitors, Q2 2026
Arcadia Biosciences Inc reported revenue contraction of 0.82 % year on year in Q2 2026, above its competitors' combined revenue change of -3.76 %.
With a net margin of -434.23 %, Arcadia Biosciences Inc reported lower profitability than its competitors (28.01 %).
Arcadia Biosciences Inc generated 0.01 % of the combined sales of its peer group, up from 0.01 % a year earlier.
Arcadia Biosciences Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Arcadia Biosciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Arcadia Biosciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Arcadia Biosciences Inc's competitor groups requires a Commercial License.
For context: the Oil And Gas Production industry grew revenue 3.4% year over year, combined, vs -0.8% for Arcadia Biosciences Inc. Arcadia Biosciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Arcadia Biosciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Arcadia Biosciences Inc | No | No | No | No |
| Competitors combined (14) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (9) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 12.50 % (1 of 8) | 12.50 % (1 of 8) | 57.10 % (4 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RKDA Stock Performance relative to its Competitors
RKDA Stock Performance relative to High-Confidence Competitors
RKDA Stock Performance relative to Similar-Size Competitors
RKDA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Dupont De Nemours Inc | 282.9% | Outperformed |
| 2 | Cf Industries Holdings inc | 282.9% | Outperformed |
| 3 | Cibus Inc | 282.9% | Outperformed |
| 4 | Lsb Industries Inc | 282.9% | Outperformed |
| 5 | Dow Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Arcadia Biosciences Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Arcadia Biosciences Inc's Comment on Competition and Industry Peers
advanced biotechnology traits. Other potentially competitive sources of improvement in crop yields include improvements in crop protection chemicals, fertilizer formulations, farm mechanization, other biotechnology, and information management. Programs to improve genetics and chemistry are generally concentrated within a relatively small number of large companies, while non-genetic approaches are underway with broader set of companies.
In general, we believe that our competitors generally fall into the following categories:
Large Agricultural Biotechnology, Seed, and Chemical Companies: According to Phillips McDougall, the leading 11 seed and trait companies as a group invested $4.1 billion in seed and trait research and development in 2013. This includes conventional and advanced plant breeding, as well as biotechnology trait development. According to Phillips McDougall, only a limited number of companies have been actively involved in new trait discovery, development, and commercialization: Monsanto, DuPont Pioneer, Syngenta, BASF, Bayer, Dow, KWS, and Genective (a joint venture between KWS and Limagrain). Many of these companies have substantially larger budgets for gene discovery, research, development, and product commercialization than we do. Some of these companies also have substantial resources and experience managing the regulatory process for new GM seed traits. Each of Monsanto, DuPont Pioneer, Syngenta, Dow, and Bayer, which accounted for 85% of the 2013 seed trait research and development spend noted above, also have significant chemical crop protection background and businesses. The trait pipelines of these companies are heavily weighted toward biotic stress traits, although they also have significant programs aimed at development of abiotic stress traits. While these companies have internal programs that may compete with our own, they also seek new traits externally and, as such, some of them either currently are, or may in the future be, our collaborators. In addition, some of these companies are currently among our sources for new trait technologies.
Trait Research and Development Companies: There are a number of companies that specialize in research and development of agricultural yield and product quality traits, and we believe that a dozen or more companies, including Evogene and Keygene, among others, are competitors in our field. We believe that these companies typically focus on a limited number of traits, and do not generally have the product development and regulatory infrastructure necessary to bring traits to market. Therefore, they typically license trait technologies to large industry players with in-house development and regulatory capabilities at a relatively early stage of development.
Companies Focused on the Development and Commercialization of Microbial Crop Enhancements: The use of microbial products to enhance crop performance via application to soil, seed, or to crops directly is an area where increased research and development activity has been underway for the past decade or more. We believe that there are more than 20 companies of varying size working in this space. There have been a number of acquisitions, including Becker Underwood by BASF, and joint collaborations in this space, but multiple independent companies remain, including Verdesian, Marrone Bioinnovations, Biagro and Bioconsortia. While these companies could be considered to compete with us as their products seek to improve crop yields, we believe that such products and our traits may be additive, or synergistic, to our future products in terms of increasing crop yields.
Companies Focused on Farming Data Management, or Precision Agriculture: Within the past several years there has been a rapid increase in technologies and companies focused on acquiring, analyzing, and acting upon data in ways that may improve farm economics via increased crop yield and more efficient management of crop production inputs. Technical approaches include weather prediction and monitoring, high-density field and crop imaging systems, precision field soil and yield mapping, and others. Companies focusing on this space include Climate Corporation (acquired by Monsanto), Farmers Business Network, Farmers Edge, Trimble, Planet Labs, Ceres Imaging, Blue River Technologies, and others. While these products are potentially competitive with us for increasing crop yields, we believe that certain of these products could also be additive or synergistic with our traits.
Agricultural Research Universities and Institutions: Given the global importance of agriculture, numerous agricultural research universities and institutions around the world focus on basic and applied research aimed at increasing crop yield. According to the Agricultural Science and Technology Indicators, global public spending on agricultural research and development in 2008 totaled $31.7 billion, having increased by 22% during the years from 2000 to 2008. Spending in 2008 in high income countries accounted for approximately 51% of the total, while spending in low and middle income countries accounted for 49% of the total. The United States was the largest contributor of public agriculture funding in 2008 with a total investment of $4.8 billion. Most of this publicly funded research is focused on basic research. Many public research programs aim to understand basic biological processes and do not necessarily engage in further development and commercialization of discovered traits. While these programs are potentially competitive with us, we view them primarily as sources of innovation that fit with our business model. We have an established track record of working closely and effectively with public research programs, including a number from the U.S., Canada, Japan, Australia, Spain, Ireland, and elsewhere.
We believe that we are uniquely positioned at the nexus of basic research and commercial product development. Unlike many companies in our space, we generally do not compete in the area of basic research. Our focus is on development and validation and, therefore, we provide a value-added link by which basic research can be brought to market. While internal programs at the largest seed and technology companies are competitive with ours in some cases, we are technology providers to some of these companies, and we have numerous collaborations with many of them. To remain competitive, we plan to pursue multiple strategies, including further building our non-GM pipeline of new technologies from basic research programs, increasing the scope and range of our field testing activities, and continuing to protect our intellectual property rights in key jurisdictions globally.
Publicly Traded Peers of Arcadia Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Arcadia Biosciences Inc | 0.82 | 4.75 |
| Honeywell International Inc | 67,093.97 | 36,130.00 |
| Dow Inc | 19,378.64 | 39,331.00 |
| Dupont De Nemours Inc | 17,658.83 | 4,701.00 |
| Cf Industries Holdings inc | 17,476.88 | 7,739.00 |
| Eastman Chemical Co | 7,303.10 | 8,865.00 |
| SUBTOTAL | 143,268.07 | 122,359.48 |
Sign in to see all competitors of Arcadia Biosciences Inc .
Sources: Arcadia Biosciences Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Arcadia Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Arcadia Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Dmc Global Inc | Named by the company | 85% |
| Uphealth Inc | Named by the company | 85% |
| Climate Corporation | Named by the company | 85% |
| Blue River Technologies | Named by the company | 85% |
| Cibus Inc | Named by the company | 85% |
| China Green Agriculture Inc | Named by the company | 85% |
| Marrone Bio Innovations Inc | Named by the company | 85% |
| Dupont De Nemours Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Arcadia Biosciences Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Arcadia Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Dupont De Nemours Inc | Diversified Industrials 52.94 % |
| Eastman Chemical Co | Advanced Materials 32.51 % |
| Mosaic Co | Phosphates 47.57 % |
| Lsb Industries Inc | Chemical 100.00 % |
| Intrepid Potash inc | Trio 53.24 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Arcadia Biosciences Inc .
Arcadia Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Arcadia Biosciences Inc | 1 | 593,250 | -1,391,375 |
| Honeywell International Inc | 67,094 | 357,723 | 81,356 |
| Dow Inc | 19,379 | 1,136,734 | -75,116 |
| Dupont De Nemours Inc | 17,659 | 313,400 | 5,600 |
| Cf Industries Holdings inc | 17,477 | 2,668,621 | 862,069 |
| Eastman Chemical Co | 7,303 | 681,923 | 34,077 |
| PEERS TOTAL | 143,267 | 648,368 | 26,465 |
Sign in to see all peers for Arcadia Biosciences Inc .
Arcadia Biosciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Dupont De Nemours Inc | United States 44.47 % |
| Mosaic Co | United States 39.43 % |
| Fmc Corporation | EMEA 40.46 % |
| American Vanguard Corporation | US 59.82 % |
| S and w Seed Co | AR 1.86 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Arcadia Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 113 companies in Arcadia Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Arcadia Biosciences Inc ranks #109 of 113 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 777, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Shell Plc | 284,848 | 19.12 % |
| 2 | Totalenergies Se | 202,172 | 13.57 % |
| 3 | Canadian Natural Resources Limited | 103,921 | 6.98 % |
| 4 | Eni Spa | 93,781 | 6.30 % |
| 5 | Eog Resources Inc | 1,234 | 5.2% |
| 6 | Slb Limited | 1,234 | 5.2% |
| 7 | Occidental Petroleum Corporation | 1,234 | 5.2% |
| 8 | Cenovus Energy Inc | 1,234 | 5.2% |
| 9 | Diamondback Energy Inc | 1,234 | 5.2% |
| 10 | Devon Energy Corp | 1,234 | 5.2% |
| 109 | Arcadia Biosciences Inc | 1 | 0.00 % |
Market cap and industry share for the rest of Arcadia Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-01.
Arcadia Biosciences Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 104 | Barnwell Industries inc | 13 | -29.23 % |
| 105 | Camber Energy Inc | 7 | -34.50 % |
| 106 | Royale Energy Inc | 6 | - |
| 107 | New Concept Energy Inc | 4 | -23.00 % |
| 108 | Altex Industries Inc | 1,234 | 12.3% |
| 109 | Arcadia Biosciences Inc | 1 | -92.14 % |
| 110 | Groove Botanicals Inc | 1,234 | 12.3% |
| 111 | Kolibri Global Energy Inc | 1,234 | 12.3% |
| 112 | Gulfslope Energy Inc | 1,234 | 12.3% |
| 113 | Himalaya Technologies Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Arcadia Biosciences Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-01. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Arcadia Biosciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Oil And Gas Production industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (170 companies). See the full Oil And Gas Production industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 34.60 % | 55.47 % (avg) | -20.9 pp |
| Operating Margin | -80.15 % | industry median | -91.6 pp |
| EBITDA Margin | -112.33 % | 11.68 % (avg) | -124.0 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 24.49 % (avg) | -24.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Arcadia Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Oil And Gas Production industry average (170 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Oil And Gas Production industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 15.6x | - |
| EV / EBITDA | - | 9.0x | - |
| P/B | 0.8x | 1.8x | -1.0x |
| Return on Equity | -339.85 % | industry aggregate | -351.84 % |
| Return on Invested Capital | -47.41 % | 5.18 % (avg) | -52.59 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Arcadia Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -63.64 % | -20.15 % | 500.00 % | -15.61 % | 46.84 % | -46.46 % | -5.35 % | -3.71 % |
| Operating Margin | -1,152.32 % | -1,657.91 % | -159.05 % | -523.98 % | -188.98 % | -261.50 % | -72.31 % | -51.46 % |
| Return on Invested Capital | -52.78 % | -59.13 % | -26.48 % | -37.15 % | -33.89 % | -38.01 % | -16.27 % | -19.79 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Arcadia Biosciences Inc's Strategic Group Map
Every company in Arcadia Biosciences Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Arcadia Biosciences Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Arcadia Biosciences Inc's BCG Growth-Share Matrix
Relative market share (vs Arcadia Biosciences Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Arcadia Biosciences Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue -0.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Arcadia Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 777 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 24.49 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Arcadia Biosciences Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Arcadia Biosciences Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Arcadia Biosciences Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Arcadia Biosciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Arcadia Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+21.6% annualized vs trailing 12 months).
Weaknesses
- Operating margin 91.6 points below the industry median.
- Return on equity 351.8 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Arcadia Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Arcadia Biosciences Inc | 0.89 | 3.49 | - |
| Honeywell International Inc | 0.51 | 1.31 | 2.10 |
| Dow Inc | 0.37 | 1.86 | 0.99 |
| Dupont De Nemours Inc | 0.62 | 2.29 | 0.28 |
| Cf Industries Holdings inc | 0.17 | 3.34 | 0.39 |
| Eastman Chemical Co | 0.05 | 1.51 | 0.84 |
Sign in to see all peers for Arcadia Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Arcadia Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Arcadia Biosciences Inc | Q2 2026 | -0.8 % | - |
| Honeywell International Inc | Q2 2026 | -6.1 % | +262.4 % |
| Dow Inc | Q1 2026 | -6.1 % | - |
| Dupont De Nemours Inc | Q2 2026 | -44.2 % | +110.0 % |
| Cf Industries Holdings inc | Q2 2026 | +17.6 % | +76.6 % |
| Eastman Chemical Co | Q2 2026 | +9.9 % | +31.4 % |
| PEERS TOTAL | -4.5 % | +156.6 % |
Sign in to see all peers for Arcadia Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Arcadia Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Arcadia Biosciences Inc | Q2 2026 | -1.5 % | - |
| Honeywell International Inc | Q2 2026 | +7.2 % | +39.4 % |
| Dow Inc | Q1 2026 | -6.2 % | -26.7 % |
| Dupont De Nemours Inc | Q2 2026 | +3.2 % | +52.0 % |
| Cf Industries Holdings inc | Q2 2026 | -5.1 % | +10.6 % |
| Eastman Chemical Co | Q2 2026 | +9.7 % | -33.3 % |
Sign in to see all peers for Arcadia Biosciences Inc .
Arcadia Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Arcadia Biosciences Inc | - | - | - |
| Honeywell International Inc | 10.74% | 17.01% | 49.57% |
| Dow Inc | - | - | - |
| Dupont De Nemours Inc | 0.33% | 0.36% | 0.51% |
| Cf Industries Holdings inc | 17.24% | 15.64% | 30.63% |
| Eastman Chemical Co | 2.93% | 3.40% | 7.34% |
Sign in to see all peers for Arcadia Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Arcadia Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Arcadia Biosciences Inc | - | 0.17 |
| Honeywell International Inc | 8.28 | 1.86 |
| Dow Inc | - | 0.49 |
| Dupont De Nemours Inc | 286.86 | 3.76 |
| Cf Industries Holdings inc | 8.48 | 2.26 |
| Eastman Chemical Co | 16.54 | 0.82 |
| PEERS AVERAGE | 28.75 | 1.17 |
Sign in to see all peers for Arcadia Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.
